仑伐替尼联合帕博利珠单抗或依维莫司对比舒尼替尼治疗晚期肾细胞癌的健康相关生活质量结局(CLEAR):一项随机3期研究
CLEAR研究评估仑伐替尼联合帕博利珠单抗对比舒尼替尼在晚期透明细胞肾细胞癌患者中的健康相关生活质量。结果显示联合组在FKSI-DRS、EORTC QLQ-C30 GHS/QOL及EQ-5D VAS的至明确恶化时间上均优于舒尼替尼,无任何量表显著偏向舒尼替尼。
要点
- 仑伐替尼联合帕博利珠单抗组至明确恶化时间在FKSI-DRS、EORTC QLQ-C30 GHS/QOL和EQ-5D VAS均优于舒尼替尼。
- 至首次恶化时间仅EQ-5D VAS在联合组显著优于舒尼替尼,其余量表无显著差异。
- 仑伐替尼联合依维莫司对比舒尼替尼的大多数HRQOL比较相似或偏向舒尼替尼。
核心结论
- 仑伐替尼联合帕博利珠单抗组患者的生活质量评分与舒尼替尼组相似或更优,尤其在至明确恶化时间方面。
- 这些结果支持仑伐替尼联合帕博利珠单抗作为晚期肾细胞癌一线治疗的有效性和安全性。
研究设计与样本
- 开放标签、随机、3期研究,在20个国家200家医院和癌症中心开展。
- 入组患者为18岁及以上、晚期透明细胞肾细胞癌、Karnofsky体能状态评分70%或以上,且未接受过既往系统性抗癌治疗。
- 患者按1:1:1随机分配至仑伐替尼(口服20 mg/日)联合帕博利珠单抗(静脉200 mg每21天)、仑伐替尼(口服18 mg/日)联合依维莫司(口服5 mg/日)21天周期、或舒尼替尼(口服50 mg/日,用药4周停2周)。
- 随机分配采用计算机生成方案,按地理区域和Memorial Sloan Kettering Cancer Center预后分组进行分层。
- 主要终点为无进展生存期(已报告),HRQOL为次要终点;大多数HRQOL分析在随机化、接受至少一剂研究治疗且有HRQOL数据的患者中进行,完成度和依从性分析在全分析集中进行。
主要发现
- FKSI-DRS自基线平均变化:仑伐替尼联合帕博利珠单抗组-1.75(SE 0.59)对比舒尼替尼组-2.19(0.66)。
- EORTC QLQ-C30 GHS/QOL自基线平均变化:联合组-5.93(0.86)对比舒尼替尼组-6.73(0.94)。
- EQ-5D VAS自基线平均变化:联合组-4.96(0.85)对比舒尼替尼组-6.64(0.94)。
- 至首次恶化时间:FKSI-DRS联合组9.14周(95%CI 6.43-12.14)对比舒尼替尼组12.14周(9.14-15.29),HR 1.13(95%CI 0.94-1.35),log-rank p=0.20;EORTC QLQ-C30 GHS/QOL联合组12.00周(7.29-15.14)对比舒尼替尼组9.14周(6.29-12.14),HR 0.88(0.74-1.05),log-rank p=0.17;EQ-5D VAS联合组9.43周(6.43-12.29)对比舒尼替尼组9.14周(6.29-12.00),HR 0.83(0.70-0.99),log-rank p=0.041。
- 至明确恶化时间:FKSI-DRS联合组134.14周(95%CI 120.00-不可估计)对比舒尼替尼组117.43周(90.14-131.29),HR 0.70(95%CI 0.53-0.92),log-rank p=0.0081;EORTC QLQ-C30 GHS/QOL联合组114.29周(102.14-153.29)对比舒尼替尼组75.14周(57.29-105.14),HR 0.60(0.47-0.77),log-rank p<0.0001;EQ-5D VAS联合组124.86周(94.71-134.57)对比舒尼替尼组74.86周(54.14-96.00),HR 0.67(0.53-0.85),log-rank p=0.0012。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma. We aimed to assess the health-related quality-of-life (HRQOL) outcomes from the CLEAR study. METHODS: This open-label, randomised, phase 3 study was done across 200 hospitals and cancer centres in 20 countries. Patients were required to be 18 years or older, with advanced clear-cell renal cell carcinoma, and a Karnofsky performance status of 70% or higher. Patients who had received previous systemic anticancer therapy for renal cell carcinoma were not eligible. Patients were randomly assigned (1:1:1) to lenvatinib (oral 20 mg per day) plus pembrolizumab (intravenous 200 mg every 21 days), lenvatinib (oral 18 mg per day) plus everolimus (oral 5 mg per day) in 21-day cycles, or sunitinib (oral 50 mg per day, 4 weeks on followed by 2 weeks off). Patients were assigned to treatments with a computer-generated randomisation scheme and were stratified by geographical region and Memorial Sloan Kettering Cancer Center prognostic groups. The primary endpoint, previously reported, was progression-free survival, and HRQOL was a secondary endpoint. Most HRQOL analyses were done in patients who underwent randomisation, received at least one dose of study treatment, and had any HRQOL data. Completion and compliance analyses were done in the full analysis set. Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms (FKSI-DRS), European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), and the EQ-5D-3 Level (EQ-5D-3L) preference questionnaire were administered at baseline and on day 1 of each subsequent 21-day cycle. This study is registered with ClinicalTrials.gov, NCT02811861, and is closed to new participants. FINDINGS: Between Oct 13, 2016, and July 24, 2019, 355 patients were randomly assigned to the lenvatinib plus pembrolizumab group, 357 to the lenvatinib plus everolimus group, and 357 to the sunitinib group. Median follow-up for HRQOL analyses was 12·9 months (IQR 5·6-22·3). Because of the promising efficacy and safety results of lenvatinib plus pembrolizumab in the first-line setting, we focus the HRQOL results in this report on that combination versus sunitinib. Mean change from baseline in the lenvatinib plus pembrolizumab group compared with the sunitinib group was -1·75 (SE 0·59) versus -2·19 (0·66) for FKSI-DRS, -5·93 (0·86) versus -6·73 (0·94) for EORTC QLQ-C30 global health status/quality of life (GHS/QOL), and -4·96 (0·85) versus -6·64 (0·94) for the EQ-5D visual analogue scale (VAS). Median time to first deterioration in the lenvatinib plus pembrolizumab group compared with the sunitinib group was 9·14 weeks (95% CI 6·43-12·14) versus 12·14 weeks (9·14-15·29; HR 1·13 [95% CI 0·94-1·35], log-rank p=0·20) for FKSI-DRS, 12·00 weeks (7·29-15·14) versus 9·14 weeks (6·29-12·14; 0·88 [0·74-1·05], log-rank p=0·17) for EORTC QLQ-C30 GHS/QOL, and 9·43 weeks (6·43-12·29) versus 9·14 weeks (6·29-12·00; 0·83 [0·70-0·99], log-rank p=0·041) for the EQ-5D VAS. Median time to definitive deterioration in the lenvatinib plus pembrolizumab group compared with the sunitinib group was 134·14 weeks (95% CI 120·00-not estimable) versus 117·43 weeks (90·14-131·29; HR 0·70 [95% CI 0·53-0·92], log-rank p=0·0081) for FKSI-DRS, 114·29 weeks (102·14-153·29) versus 75·14 weeks (57·29-105·14; 0·60 [0·47-0·77], log-rank p<0·0001) for EORTC QLQ-C30 GHS/QOL, and 124·86 weeks (94·71-134·57) versus 74·86 weeks (54·14-96·00; 0·67 [0·53-0·85], log-rank p=0·0012) for the EQ-5D VAS. No outcomes on any of the instruments significantly favoured sunitinib over lenvatinib plus pembrolizumab. Most HRQOL comparisons of lenvatinib plus everolimus versus sunitinib were similar or favoured sunitinib. INTERPRETATION: These HRQOL results demonstrate that patients given lenvatinib plus pembrolizumab treatment had similar or favourable scores compared with patients given sunitinib, particularly with respect to time to definitive deterioration. These results support the efficacy and safety profile of lenvatinib plus pembrolizumab as first-line therapy for patients with advanced renal cell carcinoma. FUNDING: Eisai (Nutley, NJ, USA) and Merck Sharp & Dohme, a subsidiary of Merck & Co (Kenilworth, NJ, USA).
引用
- Motzer R, Porta C, Alekseev B, et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Lancet Oncol. 2022. PMID: 35489363. doi:10.1016/S1470-2045(22)00212-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。